Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?
Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?
复制标题
DOI：
10.1152/ajprenal.00443.2017
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Zongwei Wang;A. Olumi
中科院分区：
文献类型：
--
作者：
Zongwei Wang;A. Olumi
已在临床实践中用于其他目的的现有药物可证明可用于再利用，因为大部分安全性特征和药代动力学已经完成。因此，药物可以进入临床实践的各种原因，监管负担较少。二甲双胍可能被证明是这样一种药物;它可能在其他疾病中发挥作用，除了糖尿病的管理。从这个角度来看，我们提供了我们的发现和二甲双胍作为治疗泌尿系异常增殖的替代方法的理解。我们将其潜在的机制分为两个特点：通过胰岛素样生长因子（IGF）信号通路直接发挥抗增殖作用和通过调节DNA甲基化进行表观遗传调节。这些特异性标志可能最终有助于更好地理解二甲双胍治疗前列腺疾病。
Existing drugs that have been used in clinical practice for other purposes can prove useful for reutilization, since much of the safety profile and pharmacokinetics have been completed. Therefore, the drugs can enter clinical practice for a variety of causes with less regulatory burden. Metformin may prove to be such a drug; it may have a role in other diseases, besides the management of diabetes. In this perspective, we provide our findings and understanding of metformin as an alternative way to treat urological abnormal proliferation. We propose the potential mechanisms into two hallmarks: direct antiproliferative function via insulin-like growth factor (IGF) signaling pathway and epigenetic modulating via adjusting DNA methylation. These specific hallmarks may ultimately contribute to a better understanding of metformin in treating prostatic diseases.